{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:07:07Z","timestamp":1773954427491,"version":"3.50.1"},"reference-count":45,"publisher":"Impact Journals, LLC","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2023,11,30]]},"DOI":"10.18632\/aging.205222","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T18:05:08Z","timestamp":1700503508000},"page":"13118-13133","source":"Crossref","is-referenced-by-count":4,"title":["Clinical significance and immune landscape of angiogenesis-related genes in bladder cancer"],"prefix":"10.18632","volume":"15","author":[{"given":"Gang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingwen","family":"Gui","sequence":"additional","affiliation":[{"name":"Department of Urology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Thyroid Surgery, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/medicina57080749","article-title":"Bladder Cancer: Current Challenges and Future Directions.","volume":"5","author":"Oszczud\u0142owski","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer.","volume":"6","author":"Lotan","year":"2013","journal-title":"Eur Urol"},{"key":"3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.","volume":"3","author":"Marquez","year":"2016","journal-title":"Cancer Cell"},{"key":"4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/cancers11030316","article-title":"Tumor Neovascularization and Developments in Therapeutics.","volume":"1","author":"Takayama","year":"2019","journal-title":"Cancers (Basel)"},{"key":"5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases.","volume":"40","author":"Jain","year":"2000","journal-title":"Nature"},{"key":"6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets.","volume":"2","author":"Larriv\u00e9e","year":"2017","journal-title":"Angiogenesis"},{"key":"7","doi-asserted-by":"publisher","first-page":"9526","DOI":"10.3390\/ijms22179526","article-title":"Fibroblast Growth Factor Inhibitors for Treating Locally Advanced\/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.","volume":"2","author":"Seo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020.","volume":"7","author":"Galsky","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.canlet.2017.06.027","article-title":"Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA\/VEGFR2 signaling pathway.","volume":"40","author":"Chen","year":"2017","journal-title":"Cancer Lett"},{"key":"10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/cac2.12158","article-title":"The role of the HIF-1\u03b1\/ALYREF\/PKM2 axis in glycolysis and tumorigenesis of bladder cancer.","volume":"4","author":"Yang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"11","doi-asserted-by":"publisher","first-page":"102000","DOI":"10.1016\/j.ctrv.2020.102000","article-title":"The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.","volume":"8","author":"Carles","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"12","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.","volume":"10","author":"Mesirov","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.","volume":"1","author":"Mark","year":"1996","journal-title":"Stat Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predictingor cancer patient drug response and biomarkers from cell line screening data.","volume":"2","author":"Huang","year":"2021","journal-title":"Brief Bioinform"},{"key":"15","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3906\/sag-2004-200","article-title":"Molecular subtyping bladder cancer: Is it ready for clinical practice?","volume":"5","author":"Vakar Lopez","year":"2020","journal-title":"Turk J Med Sci"},{"key":"16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","article-title":"Basic and therapeutic aspects of angiogenesis.","volume":"14","author":"Carmeliet","year":"2011","journal-title":"Cell"},{"key":"17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1023\/a:1016045012466","article-title":"Multiple angiogenesis stimulators in a single malignancy: implications for anti-angiogenic tumour therapy.","volume":"4","author":"Schweigerer","year":"2001","journal-title":"Angiogenesis"},{"key":"18","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.thromres.2018.01.030","article-title":"Anti-angiogenesis for cancer: Current status and prospects.","volume":"16","author":"Giavazzi","year":"2018","journal-title":"Thromb Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.2174\/0929867327666200514082425","article-title":"Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors.","volume":"2","author":"Rao","year":"2021","journal-title":"Curr Med Chem"},{"key":"20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12964-022-00838-y","article-title":"Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.","volume":"2","author":"Dadashpour","year":"2022","journal-title":"Cell Commun Signal"},{"key":"21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.","volume":"1","author":"Kerbel","year":"2009","journal-title":"Cancer Cell"},{"key":"22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.mce.2011.11.007","article-title":"Evolution and roles of stanniocalcin.","volume":"34","author":"Wong","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10585-014-9687-9","article-title":"STC1 expression is associated with tumor growth and metastasis in breast cancer.","volume":"3","author":"Anderson","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13046-022-02315-3","article-title":"Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2\/ITGB6 signaling axis in ovarian cancer.","volume":"4","author":"Wang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"25","first-page":"325","article-title":"Clinical significance of STC1 gene expression in patients with colorectal cancer.","volume":"3","author":"Tanaka","year":"2011","journal-title":"Anticancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1210\/en.2005-0365","article-title":"Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells.","volume":"14","author":"Wong","year":"2005","journal-title":"Endocrinology"},{"key":"27","first-page":"677","article-title":"Expression of vascular endothelial growth factor (VEGF) and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma.","volume":"5","author":"P\u0103iu\u015fan","year":"2010","journal-title":"Rom J Morphol Embryol"},{"key":"28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2013.04.024","article-title":"Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF\/VEGFR2 and angiopoietin signaling pathways.","volume":"37","author":"Wong","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1423-0127-18-39","article-title":"Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells.","volume":"1","author":"Hou","year":"2011","journal-title":"J Biomed Sci"},{"key":"30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00709-019-01477-w","article-title":"GATA1-regulated JAG1 promotes ovarian cancer progression by activating Notch signal pathway.","volume":"25","author":"Xie","year":"2020","journal-title":"Protoplasma"},{"key":"31","doi-asserted-by":"publisher","first-page":"e0150355","DOI":"10.1371\/journal.pone.0150355","article-title":"JAG1 Is Associated with Poor Survival through Inducing Metastasis in Lung Cancer.","volume":"1","author":"Yu","year":"2016","journal-title":"PLoS One"},{"key":"32","doi-asserted-by":"publisher","first-page":"21986","DOI":"10.1038\/s41598-022-26241-8","article-title":"JAG1 is associated with the prognosis and metastasis in breast cancer.","volume":"1","author":"Liu","year":"2022","journal-title":"Sci Rep"},{"key":"33","doi-asserted-by":"publisher","first-page":"110416","DOI":"10.1016\/j.biopha.2020.110416","article-title":"The oncogenic role of Jagged1\/Notch signaling in cancer.","volume":"12","author":"Kuang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"34","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3389\/fonc.2018.00659","article-title":"The Role of COL5A2 in Patients With Muscle-Invasive Bladder Cancer: A Bioinformatics Analysis of Public Datasets Involving 787 Subjects and 29 Cell Lines.","volume":"8","author":"Li","year":"2019","journal-title":"Front Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"e24561","DOI":"10.1097\/MD.0000000000024561","article-title":"COL5A2 as a potential clinical biomarker for gastric cancer and renal metastasis.","volume":"10","author":"Zhao","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"36","doi-asserted-by":"publisher","first-page":"583083","DOI":"10.3389\/fonc.2021.583083","article-title":"COL5A2 Promotes Proliferation and Invasion in Prostate Cancer and Is One of Seven Gleason-Related Genes That Predict Recurrence-Free Survival.","volume":"1","author":"Qin","year":"2021","journal-title":"Front Oncol"},{"key":"37","doi-asserted-by":"publisher","first-page":"BSR20204293","DOI":"10.1042\/BSR20204293","article-title":"High expression of COL5A2, a member of COL5 family, indicates the poor survival and facilitates cell migration in gastric cancer.","volume":"4","author":"Xu","year":"2021","journal-title":"Biosci Rep"},{"key":"38","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2147\/OTT.S288422","article-title":"Increased Collagen Type V \u03b12 (COL5A2) in Colorectal Cancer is Associated with Poor Prognosis and Tumor Progression.","volume":"1","author":"Liu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"39","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.3892\/ijmm.2018.3468","article-title":"Homeobox protein MSX1 inhibits the growth and metastasis of breast cancer cells and is frequently silenced by promoter methylation.","volume":"4","author":"Ren","year":"2018","journal-title":"Int J Mol Med"},{"key":"40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s12276-022-00731-1","article-title":"Hypermethylation of PDX1, EN2, and MSX1 predicts the prognosis of colorectal cancer.","volume":"5","author":"Kim","year":"2022","journal-title":"Exp Mol Med"},{"key":"41","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.3390\/ijms21124529","article-title":"MSX1-A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas.","volume":"2","author":"Heidegger","year":"2020","journal-title":"Int J Mol Sci"},{"key":"42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41419-021-04174-w","article-title":"Knockdown of OLR1 weakens glycolytic metabolism to repress colon cancer cell proliferation and chemoresistance by downregulating SULT2B1 via c-MYC.","volume":"1","author":"Zhang","year":"2021","journal-title":"Cell Death Dis"},{"key":"43","doi-asserted-by":"publisher","first-page":"108275","DOI":"10.1016\/j.intimp.2021.108275","article-title":"OLR1 is a prognostic factor and correlated with immune infiltration in breast cancer.","volume":"10","author":"Xu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41418-021-00884-y","article-title":"Targeting lectin-like oxidized low-density lipoprotein receptor-1 triggers autophagic program in esophageal cancer.","volume":"2","author":"Ruan","year":"2022","journal-title":"Cell Death Differ"},{"key":"45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.","volume":"3","author":"Peters","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T14:33:36Z","timestamp":1701873216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":45,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,30]]}},"alternative-id":["205222","37988196"],"URL":"https:\/\/doi.org\/10.18632\/aging.205222","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}